Valuation: Micromedic Technologies Ltd

Market Cap 26.25M 2.63B 8.79M 7.53M 7.04M 6.43M 12.09M 841M 12.26M 83.17M 32.42M 422M 33M 32.28M 1.4B P/E 2023
-2.52x
P/E 2024 -7.86x
Enterprise Value 26.21M 2.62B 8.78M 7.51M 7.03M 6.42M 12.07M 840M 12.24M 83.04M 32.37M 422M 32.95M 32.23M 1.39B EV / Sales 2023
-
EV / Sales 2024 57.4x
Free-Float
30.21%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 42 2020-08-11
Director of Finance/CFO 63 2022-07-09
General Counsel 55 2020-08-11
Director TitleAgeSince
Chairman 87 2011-11-20
Director/Board Member 76 2014-10-12
Director/Board Member 71 2020-08-11
Change 5-day change 1-year change 3-year change Capi.($)
+5.37%+92.48% - - 4.4M
+2.16%+5.05%+99.92%+310.58% 4.15B
-7.79%+18.77%+208.18%+29.94% 3.76B
+1.24%+2.57%+36.48%+62.79% 3.4B
+3.45%+7.26%+274.79%+480.07% 2.51B
-3.61%+3.84%-18.47%-20.90% 2.41B
-0.88%+16.87%+27.81% - 1.48B
+4.22%+51.58%+252.65%-19.48% 1.29B
-2.40%-5.13%+17.99%+39.91% 1B
-2.72%-2.82%-36.21%-1.66% 552M
Average -0.10%+11.21%+95.91%+110.16% 2.28B
Weighted average by Cap. -0.77%+10.62%+113.43%+146.05%

Financials

2023 2024
Net sales 876K 87.6M 293K 251K 235K 215K 403K 28.08M 409K 2.78M 1.08M 14.09M 1.1M 1.08M 46.62M 413K 41.3M 138K 118K 111K 101K 190K 13.24M 193K 1.31M 510K 6.64M 519K 508K 21.98M
Net income -3.88M -388M -1.3M -1.11M -1.04M -951K -1.79M -124M -1.81M -12.29M -4.79M -62.39M -4.88M -4.77M -206M -3.28M -328M -1.1M -941K -880K -805K -1.51M -105M -1.53M -10.4M -4.05M -52.8M -4.13M -4.04M -175M
Net Debt -101K -10.1M -33.82K -28.96K -27.09K -24.76K -46.51K -3.24M -47.18K -320K -125K -1.62M -127K -124K -5.38M -43K -4.3M -14.4K -12.33K -11.53K -10.54K -19.8K -1.38M -20.09K -136K -53.1K -692K -54.06K -52.88K -2.29M
Logo Micromedic Technologies Ltd
Nextage Therapeutics Ltd, formerly known asMicromedic Technologies Ltd,is an Israel-based company engaged in the development and commercialization of cancer diagnostic products. Its portfolio includes a range of cancer and cancer-related indications including colorectal cancer, breast cancer, cervical cancer, bladder cancer, lung cancer, and diagnostic tools for personalized treatment. Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence, Micromedic identifies projects that fill unmet needs in various cancer related indications, and turns them into viable marketable products. Micromedic operates through strategic collaborations and in-licensing from scientific institutes world-wide as well as in-house based research.
Employees
-